heparin
Enable an agent to recognise heparin, assess the identity, activity and condition of a recorded material or preparation, and determine which handling or use decisions require further evidence.
Research draft, second pass
A second pass drafted this model: the structure a model of this thing needs, and what is known about it in the world. The line under this one says how the second half was obtained - researched against sources, or recalled without web access, in which case nothing here was read anywhere and every claim is a lead to verify. Unreviewed either way.
recalled by Codex without web access - no source was read
Researched by: Codex
Purpose and description
Enable an agent to recognise heparin, assess the identity, activity and condition of a recorded material or preparation, and determine which handling or use decisions require further evidence.
Heparin is a heterogeneous, highly sulfated glycosaminoglycan produced by animal mast cells whose pharmaceutical preparations act as anticoagulants chiefly by enhancing antithrombin-mediated inhibition of coagulation enzymes.
It can be Compare identity and composition evidence with a declared heparin specification.; Trace a material or preparation to its source, batch and quality records.; Compare potency results only after checking methods, units and reference standards.; Identify concentration, presentation or material-class mismatches before a proposed use.; Flag material for quarantine or specialist review when identity, condition or release evidence is inadequate.; Link a proposed application to its governing protocol and preparation-specific restrictions..
Distinguishing features
Establish a heparin-compatible glycosaminoglycan identity using documented analytical evidence; an anticoagulant effect or product name alone is insufficient.
Distinguish heparin from the closely related heparan sulfate using structural and compositional evidence rather than treating the names as synonyms.
Distinguish unfractionated heparin from low-molecular-weight heparin using the declared material identity, processing history and molecular-mass distribution.
Distinguish heparin from fondaparinux and other synthetic anticoagulants using molecular identity and chain composition, even where activity involves antithrombin.
Distinguish bulk heparin material from an injection, flush solution or heparin-coated article by recording formulation and physical presentation separately.
Scope
+ Heparin identity and the distinction between a material class, a batch and a formulated preparation
+ Biological origin, extraction provenance and supply-chain traceability
+ Molecular-mass distribution, sulfation characteristics and compositional heterogeneity
+ Anticoagulant potency and the methods and reference standards used to establish it
+ Preparation identity, storage condition, contamination evidence and use constraints
- Patient-specific prescribing, dosing and anticoagulation management
- Diseases treated or prevented using heparin
- Complete medicinal-product authorisation, packaging and distribution models
- Extraction and purification equipment and manufacturing-process operation
- Independent models of low-molecular-weight heparin products and synthetic anticoagulants
Characteristics
- Material and preparation identity
- Unfractionated heparin material; formulated heparin preparation; derivative or related-material link; unresolved Prevents a substance, a derivative and a finished preparation from being treated as interchangeable.
- Biological source
- Source species, tissue and supplier records, with unknown values explicit Supports provenance assessment and interpretation of source-dependent composition.
- Salt form
- Declared counterion, such as sodium or calcium, or unresolved Identifies the supplied material and supports interpretation of specifications and mass-based measurements.
- Molecular-mass distribution
- Da or kDa; distribution and reported averages with analytical method Represents chain heterogeneity and helps distinguish material classes.
- Sulfation and disaccharide profile
- Method-defined ratios or proportions, with denominator and analytical method Provides structural evidence for identity, comparability and unusual composition.
- Anticoagulant potency
- Assay-defined activity units per mg or mL, with reference standard and assay Activity cannot be inferred reliably from material mass alone.
- Anti-factor Xa and anti-factor IIa activity
- Assay-specific activity values and dimensionless ratio where justified Helps characterise the activity profile without assuming all heparin-related materials act identically.
- Formulation composition
- Heparin concentration, total activity, solvent, preservatives and other excipients Separates active-material identity from preparation-specific suitability.
- Quality disposition
- Untested; under review; released against a named specification; quarantined; rejected; expired Makes permission to use a batch depend on evidence and applicable requirements.
- Storage and container condition
- Recorded conditions, container integrity, opening history and excursion assessment Supports preparation-specific decisions about continued usability.
Also called
Where this came from
wikidata · CC0 1.0
Drafted structure
Bundle to layer to finding to question, as the second pass will find it: 6 bundles · 11 layers · 19 findings · 29 questions.
Heparin identity and boundaries Establish what the recorded heparin entity is and separate it from related substances and preparations.
Heparin denotes a heterogeneous material, while operational records may describe a batch, medicine or surface treatment.
Material identity
Record the declared identity and evidence supporting recognition as heparin.
Identity evidence
Capture the analytical and documentary basis for the heparin designation.
- What material name and salt form are declared, and what identity method supports them? definition
- Which evidence distinguishes this material from heparan sulfate or another sulfated polysaccharide? boundary
Derivative and presentation boundaries
Separate the heparin material from derivatives and articles containing it.
Recorded entity level
Identify whether the record concerns heparin itself, a batch, a preparation or a related entity.
- Does this record describe unfractionated heparin, a formulated preparation or a derivative requiring a linked model? boundary
- If heparin is attached to a surface or incorporated into an article, which properties belong to the heparin and which to the host article? boundary
Biological origin and composition Connect source history with the structural heterogeneity of the material.
A single chemical formula or nominal mass does not adequately describe a heparin batch.
Source traceability
Document biological source and the chain of records supporting batch provenance.
Source and processing lineage
Record source species, tissue and relevant processing history without inferring missing provenance.
- What species and tissue supplied the heparin, and which records establish that origin? provenance
- Which extraction, purification or chain-modifying steps are documented for this batch? provenance
Chain composition
Represent molecular-size and structural distributions using method-specific observations.
Structural profile
Capture chain-size distribution and sulfation-related measurements that support identity and comparability.
- What molecular-mass distribution was measured, using which method and calibration? measurement
- What sulfation or disaccharide profile is available, and what uncertainty or uncharacterised fraction remains? measurement
Anticoagulant activity Represent heparin's measured biological activity and the conditions under which results are meaningful.
Mass, anticoagulant potency and activity profile describe different aspects of heparin.
Activity mechanism
Connect activity evidence to antithrombin-mediated effects and relevant assay conditions.
Activity profile evidence
Record measured anti-factor Xa and anti-factor IIa activity without turning those measurements into patient-level predictions.
- Which antithrombin-dependent activities have been measured for this material? measurement
- What assay conditions limit comparison of its anti-factor Xa and anti-factor IIa results? boundary
Potency and comparability
Maintain the connection between reported activity, assay and reference standard.
Potency basis
Keep activity units, mass basis and preparation concentration explicit.
- What potency is reported, in which units and against which reference standard? measurement
- What evidence permits comparison or conversion between the reported potency and another result or labelled concentration? boundary
Purity and quality disposition Assess identity integrity, unwanted components and batch release evidence.
An anticoagulant assay alone cannot establish heparin purity or preparation suitability.
Impurities and adulteration
Record testing for unwanted biological material and non-heparin polysaccharides.
Contaminant screening
Capture what impurity and adulterant tests establish, including their detection limits.
- Which methods were used to detect non-heparin components, including oversulfated chondroitin sulfate? measurement
- Which process-related or biological impurities remain untested or unresolved? measurement
Specification and release
Relate analytical results to an applicable specification and documented disposition.
Batch acceptability
Record who accepted the batch, for what purpose and against which requirements.
- Which specification, jurisdiction and revision govern acceptance of this material or preparation? provenance
- Do the available identity, purity, potency and applicable microbiological results support release, or require quarantine and review? action
Preparation condition and use constraints Connect heparin presentation and condition to the limits of a proposed application.
Concentration, excipients, sterility requirements and exposure context affect what may be done with a heparin preparation.
Presentation and stability
Describe the supplied preparation and evidence for continued usability.
Preparation state
Record concentration, contents, container condition and storage history.
- What activity per volume, total activity, salt form and excipients does the preparation declare? measurement
- What preparation-specific evidence determines usability after storage excursions, opening or container damage? action
Application and hazard links
Identify application-specific constraints and route clinical decisions to the appropriate model or protocol.
Proposed use review
Connect the preparation to its intended application and relevant bleeding, heparin-induced thrombocytopenia and compatibility considerations.
- Is the proposed application therapeutic, a catheter flush, laboratory anticoagulation or a material coating, and what specification governs it? boundary
- Which preparation restrictions, compatibility evidence and clinical hazard checks must the responsible protocol resolve before use? action
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.
A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.
Reported evidence
Findings from the breadth pass, kept separate from the structural claims.
Check these first
Recalled without web access and unsourced; every item is a lead to verify.
- The name can denote the biological polysaccharide family or a pharmaceutical preparation; this description covers both and distinguishes derivatives and salts.
- Molecular-mass ranges are approximate averages, not specification limits; heparin has no single molecular formula or molecular mass.
- Pharmacopoeial editions, jurisdiction-specific source permissions and product specifications require verification; these statements are recalled rather than researched.
- Which of these check these first hold for the sense of heparin this model covers, and on what evidence? provenance
Kinds and varieties
Recalled without web access and unsourced; every item is a lead to verify.
- Unfractionated heparin
- Low-molecular-weight heparins, produced by depolymerizing heparin
- Heparin sodium
- Heparin calcium
- Which of these kinds and varieties hold for the sense of heparin this model covers, and on what evidence? provenance
Identifiers and schemes
Recalled without web access and unsourced; every item is a lead to verify.
- CAS Registry Number - 9005-49-6 - Heparin; particular salts have separate identifiers.
- CAS Registry Number - 9041-08-1 - Heparin sodium.
- WHO ATC - B01AB01 - Heparin; individual low-molecular-weight heparins have separate codes.
- Which of these identifiers and schemes hold for the sense of heparin this model covers, and on what evidence? provenance
Standards and regulation
Recalled without web access and unsourced; every item is a lead to verify.
- United States Pharmacopeia-National Formulary: USP monographs for Heparin Sodium and Heparin Sodium Injection.
- European Pharmacopoeia, published by the EDQM: monographs for heparin sodium and heparin calcium.
- Which of these standards and regulation hold for the sense of heparin this model covers, and on what evidence? provenance
Real-world use
Recalled without web access and unsourced; every item is a lead to verify.
- Prevention and treatment of venous thromboembolism.
- Anticoagulation during cardiopulmonary bypass and selected vascular procedures.
- Prevention of clotting in extracorporeal circuits, including haemodialysis.
- Maintaining patency of certain vascular access devices using designated preparations.
- Anticoagulant in selected laboratory blood-collection tubes.
- Which of these real-world use hold for the sense of heparin this model covers, and on what evidence? provenance
Typical measurements
Recalled without web access and unsourced; every item is a lead to verify.
- Approximate average molecular mass of unfractionated heparin - 12-18 - kDa
- Approximate average molecular mass of low-molecular-weight heparins - 4-6 - kDa
- Which of these typical measurements hold for the sense of heparin this model covers, and on what evidence? provenance
Failure modes and hazards
Recalled without web access and unsourced; every item is a lead to verify.
- Bleeding, including potentially fatal haemorrhage.
- Immune-mediated heparin-induced thrombocytopenia, which can cause thrombosis despite a falling platelet count.
- Medication errors involving preparation concentration, potency units or confusion between flush and therapeutic products.
- Osteoporosis with prolonged exposure and hyperkalaemia associated with suppression of aldosterone.
- Contamination or adulteration of animal-derived material, historically including oversulfated chondroitin sulfate.
- Which of these failure modes and hazards hold for the sense of heparin this model covers, and on what evidence? provenance
Regional variation
Recalled without web access and unsourced; every item is a lead to verify.
- Permitted animal sources and availability of porcine- or bovine-derived preparations vary by jurisdiction.
- Marketed salts, concentrations and approved indications vary between countries.
- Which of these regional variation hold for the sense of heparin this model covers, and on what evidence? provenance
Neighbouring kinds and how to tell them apart
Recalled without web access and unsourced; every item is a lead to verify.
- Heparan sulfate - A related glycosaminoglycan generally less sulfated than heparin and widely associated with cell surfaces and extracellular matrices.
- Enoxaparin - A specific low-molecular-weight heparin preparation with defined manufacturing and pharmaceutical characteristics.
- Fondaparinux - A synthetic pentasaccharide that selectively enhances antithrombin-mediated factor Xa inhibition rather than a heterogeneous heparin polymer preparation.
- Warfarin - A vitamin K antagonist that reduces synthesis of functional vitamin K-dependent coagulation proteins rather than enhancing antithrombin activity.
- Which of these neighbouring kinds and how to tell them apart hold for the sense of heparin this model covers, and on what evidence? provenance
What the second pass must settle
- Does the registry intend heparin to mean unfractionated heparin specifically, or a broader parent concept that links to low-molecular-weight derivatives?
- Which authoritative definitions and analytical criteria should govern the boundary between heparin and heparan sulfate?
- Which current pharmacopoeial specifications and reference standards apply to the intended jurisdictions and applications?
- Which source-dependent composition differences are sufficiently established to affect identity, comparability or acceptance decisions?
- What preparation-specific stability, compatibility and release evidence is available, and which gaps must remain explicitly unresolved?